June 25, 2007 -- Skystar Bio-Pharmaceutical Company announced it has begun in-house production of more than a dozen microbial strains, which are used to produce the company’s microorganism products. By producing its own raw materials, the company’s cost for the microorganisms will drop by $1.35 million in 2007, a 90% decrease. Over half of Skystar’s revenues comes from microorganisms. Skystar makes vaccines, microorganisms and veterinary medications. More details...
